---
title: "AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278280735.md"
description: "AFT Pharmaceuticals has won a Court of Appeal ruling in New Zealand, dismissing PBL Solutions' claim for profit-sharing from the use of its skin medicine Pascomer for non-orphan indications. The judgment confirms that profit-sharing is limited to orphan drug applications, ensuring AFT retains control over the more lucrative Port Wine Stain market. AFT does not anticipate any significant impact on its FY 2026 earnings guidance, providing clarity for investors regarding future returns from this asset."
datetime: "2026-03-08T20:52:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278280735.md)
  - [en](https://longbridge.com/en/news/278280735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278280735.md)
---

# AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.

AFT Pharmaceuticals has secured a favourable Court of Appeal judgment in New Zealand, which dismissed a claim by PBL Solutions for a share of any profits from the use of AFT’s topical skin medicine Pascomer in treating Port Wine Stains, a non-orphan indication. The ruling confirms that profit-sharing with PBL remains limited to orphan drug applications of Pascomer, with costs of the appeal shared, and AFT does not expect any material impact on its FY 2026 earnings guidance, reinforcing certainty over future economics from a potentially much larger non-orphan market.

The dispute centred on whether PBL, a 35% shareholder in AFT Orphan Pharmaceuticals, was entitled to share in profits from broader, non-orphan uses of Pascomer beyond rare-disease indications. By upholding the earlier High Court decision and keeping non-orphan profits outside the shared pool, the judgment supports AFT’s control over the more commercially significant Port Wine Stain opportunity, providing clarity for investors on the company’s rights to future returns from this asset.

**More about AFT Pharmaceuticals Ltd.**

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across over-the-counter, prescription and hospital channels. Its products, including patented, branded and generic drugs, are sold in core markets such as Australia, New Zealand, parts of Asia, North America and Europe, with out-licensing agreements extending its reach to more than 125 countries.

**Average Trading Volume:** 1,508

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** A$307.7M

For a thorough assessment of AFP stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [AFP.AU](https://longbridge.com/en/quote/AFP.AU.md)
- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [Waterloo Capital L.P. Invests $1.78 Million in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/288260787.md)
- [Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?](https://longbridge.com/en/news/288312641.md)
- [DoubleLine Income Solutions Fund Declares June 2026 Distribution | DSL Stock News](https://longbridge.com/en/news/288280311.md)
- [Alexandria Real Estate Equities, Inc. Declares Cash Dividend of $0.72 per Common Share for 2Q26](https://longbridge.com/en/news/288274171.md)
- [Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052](https://longbridge.com/en/news/288762229.md)